生物活性：Rasagiline-13C3 (mesylate racemic) is a 13C-labeled Rasagiline mesylate racemic. Rasagiline mesylate racemic is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor[1]. Rasagiline-13C3 (mesylate racemic) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
体外研究(In Vitro)：Rasagiline mesylate racemic is the racemic mixture of Rasagiline mesylate. Rasagiline mesylate is a highly potent selective irreversible MAO inhibitor with IC50s of 4.43 nM and 412 nM for rat brain MAO B and A activity, respectively[1].
瑞禧生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Rasagiline-13C3 mesylate racemic 相关抗体:
Monoamine Oxidase A Antibody (YA2036)
Monoamine Oxidase B Antibody (YA2039)
Clinical Trial
NCT NumberSponsorConditionStart DatePhaseNCT01187888Prof. Dr. Stefan Lorenzl|Teva Branded Pharmaceutical Products R&D, Inc.|Ludwig-Maximilians - University of MunichProgressive Supranuclear PalsyJanuary 2010Phase 3NCT00203060Teva Neuroscience, Inc.|Teva Branded Pharmaceutical Products R&D, Inc.Parkinson´s DiseaseJuly 1997Phase 3NCT01532141Bial - Portela C S.A.Parkinson DiseaseNovember 2009Phase 1 NCT02789020University of Florida|National Institute of Neurological Disorders and Stroke (NINDS)Parkinson´s DiseaseDecember 2016Phase 2NCT00977665Teva Branded Pharmaceutical Products R&D, Inc.|H. Lundbeck A+SMultiple System AtrophyDecember 2009Phase 2NCT01652313H. Lundbeck A+SParkinson´s DiseaseMay 2012Phase 1NCT01155479Merck Sharp & Dohme LLCParkinson DiseaseJuly 6, 2010Phase 3NCT01032486Teva Branded Pharmaceutical Products R&D, Inc.Parkinson´s DiseaseDecember 2009NCT02337764TakedaParkinson´s DiseaseFebruary 3, 2015Phase 3NCT05611372Second Affiliated Hospital, School of Medicine, Zhejiang University|Beijing Tiantan Hospital|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Jiangsu Province Nanjing Brain Hospital|The First Affiliated Hospital of Anhui Medical University|Huashan Hospital|Second Affiliated Hospital of Soochow University|Guizhou Medical University|The First Affiliated Hospital of Guangzhou Medical University|West China Hospital|Sir Run Run Shaw Hospital|The Affiliated Hospital of Hangzhou Normal University|The First Affiliated Hospital of Dalian Medical University|Qilu Hospital of Shandong University|Fujian Medical University Union HospitalREM Sleep Behavior Disorder|Parkinson Disease|SynucleinopathiesJanuary 1, 2023Phase 2|Phase 3NCT02359552The Cleveland ClinicAlzheimer´s DiseaseMay 2015Phase 2NCT00203164Teva Branded Pharmaceutical Products R&D, Inc.Parkinson´s DiseaseMay 2002Phase 3NCT01385735St. Josef Hospital BochumParkinson DiseaseOctober 2011Phase 4NCT01442610Technische Universität Dresden|Teva Branded Pharmaceutical Products R&D, Inc.Sleep Disturbances|Parkinsons´s DiseaseOctober 2011Phase 4NCT01055379Lundbeck Italia S.p.A.|Teva Branded Pharmaceutical Products R&D, Inc.Depressive Symptoms|Parkinson´s DiseaseMarch 2010Phase 4NCT01736891Chongqing Fortune Pharmaceutical Co., Ltd.|Beijing Bionovo Medicine Development Co., Ltd.Parkinson´s DiseaseNovember 2011Phase 3NCT01532128Bial - Portela C S.A.Parkinson DiseaseNovember 2009Phase 1NCT01382342Brown University|Teva Pharmaceuticals USAParkinson´s DiseaseJune 2011Phase 4NCT01007630The Parkinson´s Institute|Teva Neuroscience, Inc.Parkinson´s DiseaseNovember 2009Phase 4NCT00696215Istanbul UniversityParkinson´s DiseaseJune 2007Phase 4NCT01049984Teva Neuroscience, Inc.|H. Lundbeck A+S|Teva Branded Pharmaceutical Products R&D, Inc.Parkinson´s DiseaseDecember 2009Phase 4NCT02337725TakedaParkinson´s DiseaseFebruary 7, 2015Phase 3NCT00399477Teva Neuroscience, Inc.|Teva Branded Pharmaceutical Products R&D, Inc.Parkinson´s DiseaseOctober 2006Phase 4NCT03329508Pharma Two B Ltd.Parkinson Disease|Early Parkinson´s DiseaseJanuary 19, 2018Phase 3NCT01497652Georgetown University|Teva Neuroscience, Inc.Parkinson´s DiseaseJanuary 2012Phase 4NCT01178047University of Zurich|H. Lundbeck A+SParkinson´s DiseaseSeptember 2011Phase 4NCT02278588State University of New York at BuffaloParkinson´s DiseaseNovember 2014NCT00203125Teva Branded Pharmaceutical Products R&D, Inc.Parkinson´s DiseaseOctober 2000Phase 3NCT02337738TakedaParkinson´s DiseaseJanuary 27, 2015Phase 2|Phase 3NCT00203177Teva Branded Pharmaceutical Products R&D, Inc.Parkinson´s DiseaseOctober 2001Phase 3NCT01879241University of UlmAmyotrophic Lateral SclerosisJune 2013Phase 2NCT00203034Teva Branded Pharmaceutical Products R&D, Inc.Parkinson´s DiseaseMay 2000Phase 3NCT01168596University of FloridaParkinson´s DiseaseDecember 2009Phase 4NCT01879748Teva Branded Pharmaceutical Products R&D, Inc.Parkinson´s DiseaseJune 2013Phase 1NCT02337751TakedaParkinson´s DiseaseJuly 10, 2015Phase 3NCT00104273Teva Branded Pharmaceutical Products R&D, Inc.|Eisai Inc.Dementia|Alzheimer´s DiseaseAugust 2004Phase 2NCT00203138Teva Branded Pharmaceutical Products R&D, Inc.Parkinson´s DiseaseJune 2004Phase 3NCT00492336University of Maryland, Baltimore|Stanley Medical Research InstituteSchizophreniaJanuary 2007Phase 4NCT00936676Teva Branded Pharmaceutical Products R&D, Inc.|Teva Neuroscience, Inc.|H. Lundbeck A+SParkinson´s DiseaseJuly 2009NCT01786603Richard Barohn, MD|University of Kansas Medical CenterAmyotrophic Lateral Sclerosis (ALS)November 21, 2013Phase 2NCT01155466Merck Sharp & Dohme LLCParkinson DiseaseJuly 14, 2010Phase 3NCT03727139TakedaParkinson´s DiseaseNovember 1, 2018NCT01192503University of Virginia|Teva Neuroscience, Inc.Restless Legs SyndromeSeptember 2010Phase 2|Phase 3NCT00755027Fundació Institut de Recerca de l´Hospital de la Santa Creu i Sant PauParkinson´s DiseaseSeptember 2008Phase 4NCT01048229Qualissima|H. Lundbeck A+SEarly-stage Parkinson´s DiseaseOctober 2008Phase 4NCT00256204Teva Branded Pharmaceutical Products R&D, Inc.Parkinson´s DiseaseNovember 2005Phase 3NCT01215227Merck Sharp & Dohme LLCParkinson Disease|Idiopathic Parkinson DiseaseNovember 18, 2010Phase 3NCT02068625Insel Gruppe AG, University Hospital BernRetinal DetachmentSeptember 2010Phase 4NCT01723228Teva Branded Pharmaceutical Products R&D, Inc.Parkinson´s DiseaseNovember 2012Phase 4NCT00955604Teva Branded Pharmaceutical Products R&D, Inc.Serotonin SyndromeJuly 2009NCT01556165H. Lundbeck A+SParkinson´s DiseaseApril 2012Phase 3NCT01232738Yunxia Wang, MD|Western ALS Study Group|University of Kansas Medical CenterAmyotrophic Lateral Sclerosis (ALS)December 2011Phase 2
分子量：270.32
Formula：C1013C3H17NO3S
CAS 号：1216757-55-9
非标记 CAS：161735-79-1
性状：固体
颜色：White to off-white
中文名称：外消旋甲磺酸雷沙吉兰 13C3
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (534 KB)
产品使用指南 (1538 KB)
参考文献
[1]. M B Youdim, et al. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol. 2001 Jan;132(2):500-6.
 [Content Brief]